Navigation Links
Pieris Presents Preclinical Data for PRS-080 Hepcidin Antagonist Anticalin(R) Program at ASH Annual Meeting
Date:12/13/2011

SAN DIEGO, California, December 13, 2011 /PRNewswire/ --

-- Breadth of Pharmacokinetic Data Points to Tunable Half-life for Platform --

Pieris AG presented novel preclinical in vitro and in vivo data for its PRS-080 Anticalin hepcidin antagonist in an oral presentation at the American Society of Hematology Annual Meeting, the company announced today.  In a presentation entitled "Discovery and Preclinical Characterization of a Novel Hepcidin Antagonist with Tunable PK/PD Properties for the Treatment of Anemia in Different Patient Populations", the results demonstrated Pieris' PRS-080's ability to increase the serum iron levels in preclinical models by binding the hepcidin target with high affinity and specificity, while offering the flexibility of a tunable pharmacokinetic (PK) and pharmacodynamic (PD) profile.

"These studies in multiple preclinical species and models demonstrate the high level of control offered by the Anticalin approach in combination with PEGylation to create 'fit for purpose' PK/PD profiles that can match specific target biology across different patient populations," stated Laurent Audoly, Ph.D., Chief Scientific Officer of Pieris.  "In particular, the clear relationship between PEG formats and the resulting PK/PD profile for several PRS-080 variants tested in animal models provides an extremely encouraging basis for a rapid advance toward the clinic and creates a portfolio of molecules adapted for different hepcidin-dependent diseases."

The presentation at ASH included several in vivo animal studies of PRS-080's sub-nanomolar potency in binding hepcidin, which is a small peptide that plays a pivotal role in the regulation of iron levels in the blood.  In addition, Pieris researchers documented reliable drug half-life levels dependent on the size of the PEGylated compound.  In several preclinical models, a single dose of four different formulations of PRS-080 showed clear correlation between the PEGylation size and the pharmacokinetic properties.  Based on these data and the clinical experience from a recently completed Phase I trial with a separate compound, PRS-050, Pieris researchers predict a high level of confidence in defining the best half-life profile for treating anemia in patients.  The lead PRS-080 program candidate is projected to enter human clinical trials in the first half of 2013.

Hepcidin is a liver-derived peptide that regulates iron homeostasis in the blood. Produced in response to iron overload and inflammation, hepcidin decreases iron absorption.  When over-expressed, the peptide is associated with the development of anemia, often the result of chronic kidney disease, cancer, cancer treatments such as chemotherapy, and other inflammatory diseases.

Anticalins are therapeutic proteins derived from human lipocalins, rationally engineered to solve for the pharmacological and pharmaceutical limitations of both protein and non-protein based drug platforms.

About Pieris

Pieris AG is an independent, clinical-staged biotechnology company advancing its proprietary Anticalin® technology to create differentiated drugs that are safer and more effective than conventional approaches.  Exclusive to Pieris, Anticalin-based drugs promise to address high-unmet medical needs and expand the therapeutic potential of current targeted approaches.  Pieris' pipeline ranges from its lead compound, PRS-050 (anti-VEGF, oncology) that recently completed a Phase I clinical trial, to multiple Anticalins in preclinical development across a range of therapeutic areas.  The company has four ongoing discovery and development collaborations: Daiichi Sankyo, Takeda San Francisco, the Sanofi Group and Allergan.  Privately held, Pieris has been funded by premier biotechnology-focused venture capital, including lead investors OrbiMed Advisors and Global Life Science Ventures. For more information, please visit: http://www.pieris-ag.com.

 

For further information, please contact:

Dr. Andreas Hohlbaum
Vice President, Strategic Research and Project Management
Pieris AG
or
Gretchen Schweitzer
+49-172-861-8540
media@pieris-ag.com

Additional information is available at http://www.pieris-ag.com.

Anticalin®, Anticalins® are registered trademarks of Pieris AG.



'/>"/>
SOURCE Pieris AG
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Wacker Validates Scalability of Anticalin(R) Production With E.coli Secretion Technology and Will Produce Pieris First Clinical Candidate PRS-050
2. Pieris Reports Development Progress for Anticalin(R) PRS-050, a Next Generation VEGF Antagonist
3. Pieris Announces Results and Successful Completion of its PRS-050 Anticalin Phase I Trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
4. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
5. EntreMed Presents Data for Phase 2 Study of MKC-1 in Metastatic Breast Cancer
6. Pharmasset Presents R7128 Phase 1 Single Ascending Dose Study in Healthy Volunteers
7. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
8. CEL-SCI Presents Data for CEL-1000 as a Vaccine Adjuvant with Recombinant Hepatitis B Virus Protein
9. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
10. Targanta Presents First Data Demonstrating In Vitro Activity and In Vivo Efficacy of Prodrugs in Osteomyelitis Models
11. Wyeth Presents Phase 3 Fracture Data for Bazedoxifene, an Investigational Therapy for Osteoporosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
(Date:6/23/2016)... 23, 2016 Research and Markets has ... - Forecast to 2022" report to their offering. ... for the patients with kidney failure, it replaces the function ... the patient,s blood and thus the treatment helps to keep ... in balance. Increasing number of ESRD patients ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
Breaking Medicine Technology:
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell Observance ... and the benefits of holistic treatments, Serenity Recovery Center of Marne, Michigan, ... Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood cells, ...
(Date:6/24/2016)... ... 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 Florida ... their peers for this recognition are considered among the top 2 percent of lawyers ... as members of this year’s Legal Elite Hall of Fame: Miami Shareholders Mark ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain Relief Products, ... minimum wage raise to $12 an hour by 2020 and then adjusting it yearly to ... value of the minimum wage, assure the wage floor does not erode again, and make ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, affiliated ... Weintraub as a prominent plastic surgeon and the network’s newest partner. , ... most handsome men, look naturally attractive. Plastic surgery should be invisible.” He stands ...
(Date:6/24/2016)... ... June 24, 2016 , ... National recruitment firm Slone ... executive with extensive sequencing and genomics experience, as Vice President of North American Capital ... will be responsible for leading the sales team in the commercialization of the HTG ...
Breaking Medicine News(10 mins):